Evidence map›Paper›PMID 41050315›Full record

ArticleInternational journal of general medicine2025

A Six-Gene Mitochondrial Signature Predicts Prognosis in Dedifferentiated Thyroid Cancer.

Chenghui Lu, Xufu Wang

Abstract read
In one paragraph

Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chenghui LuDepartment of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.ORCID 0000-0003-0000-9032
Xufu WangDepartment of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dedifferentiated thyroid cancer (DDTC) is a highly malignant, infiltrative neoplasm. Studies confirm mitochondrial (MD) dysfunction links to DDTC's aggressiveness and treatment resistance via regulating energy metabolism reprogramming, exacerbating oxidative stress, and mediating apoptotic resistance. This study explored the role of MD related genes (MDRGs) in DDTC prognosis to inform prognostic evaluation and targeted therapy. Methods: In this study, DDTC prognostic genes were identified through integrated analyses, including differential analysis, weighted gene co-expression network analysis (WGCNA), univariate Cox regression, and machine Learning. Subsequently, risk model and nomogram were constructed. Functional enrichment analysis explored prognosis-related pathways, while immune infiltration analysis revealed distinct immune cell infiltration patterns between high- and low-risk groups. Additionally, drug sensitivity analysis and drug prediction identified potential therapeutic targets for DDTC. Finally, prognostic gene expression was validated using quantitative real-time polymerase chain reaction (qRT-PCR). Results: A total of 6 MDRGs were obtained. Both risk model and nomogram demonstrated robust predictive performance. Furthermore, high-risk group was closely associated with DDTC prognosis, particularly involving pathways such as cytokine receptor interaction and biological processes like cytokine activity, which were related to immune regulation and emerged as critical drivers of DDTC progression. The 4 immune cells between the high- and low-risk groups were markedly different, such as activated CD4 memory T cells and plasma cells. Drug sensitivity analysis indicated that 40 and 27 medications sensitive to high- and low-risk groups, respectively. A total of 41 drugs were predicted to have potential therapeutic effects, including omarigliptin, bepridil and bortezomib. Finally, qRT-PCR validation demonstrated that SLC26A4, KCNQ1, PMAIP1, DPP4, and NOX4 had expression trends consistent with public database results. Conclusion: This study identified 6 MDRGs (SLC26A4, SLC25A37, KCNQ1, PMAIP1, DPP4 and NOX4) associated with the prognosis of DDTC, providing valuable scientific insights and references for the targeted therapy and patient stratification of DDTC.

Indexed as

mitochondrial dysfunctionprognosisrisk modelthyroid cancer

Identifiers

PMID41050315
PMCPMC12493110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.